Download Sample
Add to CartGlobal Intranasal Corticosteroids Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Drug Types;
Prescribed Drugs, Beclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone Furoate, Fluticasone Propionate, Mometasone, Triamcinolone, OTC Drugs, Budesonide, Fluticasone Furoate, Fluticasone Propionate, and Triamcinolone.By Indication;
Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis (SAR), and Nonallergic Rhinitis.By Dosage form;
Intranasal Drops and Intranasal Sprays.By End User Type;
Hospital Pharmacies, Drug Stores, Retail Pharmacies, and Online Pharmacies.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Intranasal Corticosteroids Market (USD Million), 2021 - 2031
In the year 2024, the Global Intranasal Corticosteroids Market was valued at USD 7,056.05 million. The size of this market is expected to increase to USD 9,862.56 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.9%.
The global intranasal corticosteroids market is experiencing significant growth, driven by a variety of factors including rising prevalence of allergic rhinitis, increasing awareness about effective treatment options, and advancements in pharmaceutical formulations. Intranasal corticosteroids are widely recognized for their efficacy in treating nasal inflammation and symptoms associated with allergies, making them a preferred choice for both healthcare providers and patients. These medications, administered through the nasal route, offer a targeted approach to reduce inflammation, congestion, and other related symptoms, ensuring better patient compliance and outcomes compared to oral medications.
The market's expansion is also fueled by the growing demand for over-the-counter (OTC) products, as consumers seek convenient and accessible treatment options for managing allergy symptoms. Leading pharmaceutical companies are continuously investing in research and development to innovate and improve the efficacy and safety profiles of intranasal corticosteroids. This has led to the introduction of new formulations with enhanced delivery mechanisms, such as aqueous sprays and dry powder inhalers, which cater to the diverse needs of patients.
The increasing global burden of respiratory diseases and environmental factors contributing to allergies underscore the importance of effective management strategies. With the rising awareness of allergic conditions and their impact on quality of life, the demand for effective treatment options like intranasal corticosteroids is poised to grow. Additionally, favorable reimbursement policies and the introduction of generic versions are making these treatments more accessible to a broader population, further driving market growth.
Overall, the global intranasal corticosteroids market is set to expand robustly in the coming years, supported by advancements in drug formulations, heightened awareness, and increasing consumer demand for effective allergy management solutions. As pharmaceutical companies continue to innovate and address the evolving needs of patients, the market is expected to witness sustained growth and development.
Global Intranasal Corticosteroids Market Recent Developments
-
In January 2022, Intersurgical acquired Pulmodyne, a USA and Malaysian-based manufacturer specializing in innovative airway and respiratory products for use in prehospital, emergency care, critical care, and the home. The acquisition provides Intersurgical with an enhanced presence in the USA market and an opportunity for increased sales of the Pulmodyne ranges through the extensive global Intersurgical network.
-
In June 2022, World Allergy Organization conducted World Allergy Week to raise awareness of the impact of allergic diseases in the global communities. The theme for World Allergy Week 2022 was respiratory allergic diseases, including asthma.
Segment Analysis
The market is categorized into various drug types such as fluticasone, budesonide, beclomethasone, mometasone, and others. Fluticasone dominates the market due to its widespread use and effectiveness in treating allergic rhinitis and other nasal conditions. Mometasone and budesonide also hold significant shares due to their efficacy and fewer side effects, making them popular choices among healthcare providers.
Intranasal corticosteroids are primarily used for managing allergic rhinitis, nasal polyps, and sinusitis. Allergic rhinitis is the leading application segment, driven by the high prevalence of allergies globally and the effective symptomatic relief provided by these medications. The rise in urban pollution and lifestyle changes are contributing to the increasing cases of allergic rhinitis, further propelling the demand for intranasal corticosteroids. Treatment of nasal polyps and sinusitis also represents a substantial market segment, as these conditions require effective long-term management strategies.
The end-user segment includes hospitals, clinics, and homecare settings. Hospitals and clinics dominate the market owing to the higher volume of patient visits and the availability of specialized healthcare providers. However, there is a growing trend of self-medication and homecare management, particularly for chronic conditions like allergic rhinitis, which is boosting the market share of the homecare segment. The ease of use and accessibility of intranasal corticosteroids make them a convenient option for patients to manage their symptoms at home.
Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America leads the market, attributed to the high prevalence of allergic conditions, advanced healthcare infrastructure, and high awareness about intranasal corticosteroids. Europe follows closely, driven by similar factors along with a robust pharmaceutical industry. The Asia-Pacific region is expected to witness the fastest growth due to increasing healthcare expenditure, rising awareness about allergic diseases, and improving healthcare infrastructure. Latin America and the Middle East & Africa hold smaller market shares but are expected to grow steadily due to improving economic conditions and healthcare facilities.
In summary, the global intranasal corticosteroids market is diverse and dynamic, influenced by factors such as drug efficacy, prevalence of nasal conditions, and regional healthcare developments. Each segment offers specific opportunities and challenges that shape the market's evolution.
Global Intranasal Corticosteroids Segment Analysis
In this report, the Global Intranasal Corticosteroids Market has been segmented by Drug Types, Indication, End User Type, and Geography.
Global Intranasal Corticosteroids Market, Segmentation by Drug Types
The Global Intranasal Corticosteroids Market has been segmented by Drug Types into Prescribed Drugs, Beclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone Furoate, Fluticasone Propionate, Mometasone, Triamcinolone, Budesonide, Fluticasone Furoate, Fluticasone Propionate and Triamcinolone.
Among the prescribed intranasal corticosteroids, several key drugs stand out. Beclomethasone is widely utilized for its efficacy in reducing nasal inflammation and congestion. Budesonide is another popular choice, known for its potent anti-inflammatory properties and safety profile. Ciclesonide, a prodrug that is activated in the nasal mucosa, offers targeted action with minimal systemic absorption. Flunisolide, though less commonly prescribed, remains an option due to its effectiveness in treating nasal symptoms. Fluticasone furoate and fluticasone propionate are highly favored for their robust clinical efficacy and favorable side effect profiles. Mometasone is often preferred for its strong anti-inflammatory action and minimal adverse effects. Triamcinolone, available in several formulations, provides versatile options for managing nasal symptoms.
The OTC segment of the intranasal corticosteroids market also features prominent drugs that have transitioned from prescription status due to their safety and effectiveness. Budesonide, fluticasone furoate, fluticasone propionate, and triamcinolone are commonly available without a prescription, making them accessible for self-care in managing allergic rhinitis. These OTC options provide convenient and effective treatment for individuals seeking relief from nasal inflammation and congestion without needing a doctor's prescription.
Overall, the global intranasal corticosteroids market is characterized by a wide range of drug types catering to both prescribed and OTC categories. Each drug offers unique benefits, contributing to comprehensive management options for patients suffering from nasal inflammatory conditions. This market continues to evolve with advancements in drug formulations and delivery mechanisms, enhancing the efficacy and convenience of intranasal corticosteroid therapy.
Global Intranasal Corticosteroids Market, Segmentation by Indication
The Global Intranasal Corticosteroids Market has been segmented by Indication into Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis (SAR) and Nonallergic Rhinitis.
Perennial Allergic Rhinitis (PAR) represents a substantial segment within the Global Intranasal Corticosteroids Market. PAR is characterized by year-round symptoms caused by allergens such as dust mites, pet dander, and mold. Patients with PAR require consistent and effective treatment to manage their symptoms, making intranasal corticosteroids an ideal option due to their potent anti-inflammatory properties. The chronic nature of PAR drives a continuous demand for these medications, contributing significantly to market growth.
Seasonal Allergic Rhinitis (SAR), commonly known as hay fever, is another critical segment. SAR occurs in response to seasonal allergens like pollen, which are prevalent during specific times of the year. The cyclical nature of SAR leads to a predictable spike in demand for intranasal corticosteroids during allergy seasons. These medications are highly effective in reducing the inflammation and symptoms associated with SAR, providing relief to a large population affected by seasonal allergies. The recurring nature of SAR ensures a steady market for intranasal corticosteroids, especially during peak allergy periods.
Nonallergic Rhinitis encompasses a variety of conditions that cause nasal inflammation and symptoms similar to allergic rhinitis but are not triggered by allergens. This segment includes conditions such as vasomotor rhinitis, which can be induced by irritants like smoke, strong odors, and changes in weather or temperature. Intranasal corticosteroids are often prescribed for nonallergic rhinitis due to their ability to reduce nasal inflammation regardless of the underlying cause. The broad application of these medications for various nonallergic conditions supports the growth of this market segment.
In summary, the segmentation of the Global Intranasal Corticosteroids Market by indication into Perennial Allergic Rhinitis, Seasonal Allergic Rhinitis, and Nonallergic Rhinitis highlights the diverse therapeutic applications and the continuous demand for these medications. Each segment addresses specific patient needs, contributing to the overall expansion and dynamism of the market. The effectiveness of intranasal corticosteroids in managing different forms of rhinitis ensures their continued relevance and adoption in global healthcare practices.
Global Intranasal Corticosteroids Market, Segmentation by Dosage Form
The Global Intranasal Corticosteroids Market has been segmented by Dosage Form into Intranasal Drops and Intranasal Sprays.
Intranasal Drops are a popular dosage form for delivering medication through the nasal cavity. This method involves liquid medication being administered drop-by-drop into the nostrils. Intranasal drops are often used for their rapid absorption properties, allowing active ingredients to bypass the digestive system and enter the bloodstream quickly. This is particularly beneficial for medications that need to take effect swiftly, such as those used for pain relief, allergy treatments, and decongestants. The simplicity and ease of use make intranasal drops suitable for both self-administration and medical settings. However, they can require precise handling to avoid dosage inconsistencies and may not be as convenient for larger volumes of medication.
Intranasal Sprays, on the other hand, provide a more efficient and even distribution of medication across the nasal mucosa. This dosage form involves a fine mist being sprayed into the nostrils, which can cover a larger area of the nasal passage and ensure uniform application. Intranasal sprays are often preferred for their ease of use and ability to deliver consistent dosages, which can improve patient adherence to treatment regimens. They are used in various applications, including the treatment of allergic rhinitis, nasal congestion, and even for emergency medication delivery, such as naloxone for opioid overdoses. The design of intranasal spray devices helps minimize the risk of contamination and ensures that the medication is evenly distributed for optimal absorption.
Both intranasal drops and sprays are effective delivery methods that offer advantages over oral administration, especially for medications that require fast action or need to bypass the gastrointestinal tract to enhance bioavailability. The choice between drops and sprays often depends on the specific treatment requirements, patient preferences, and the desired speed of absorption.
Global Intranasal Corticosteroids Market, Segmentation by End User Type
The Global Intranasal Corticosteroids Market has been segmented by End User Type into Hospital Pharmacies, Drug Stores, Retail Pharmacies and Online Pharmacies.
Hospital pharmacies represent a significant portion of this market due to the high volume of prescriptions filled in hospital settings. Patients admitted to hospitals or visiting outpatient departments often receive prescriptions for intranasal corticosteroids as part of their treatment plan. The convenience of obtaining medications directly from hospital pharmacies ensures that patients start their treatment promptly, contributing to this segment's substantial market share.
Drug stores and retail pharmacies are also key players in the intranasal corticosteroids market. These establishments are highly accessible to the general public, making it easy for patients to purchase over-the-counter or prescription intranasal corticosteroids. Retail pharmacies, in particular, benefit from their widespread presence and the trust they have built with local communities. Their ability to provide personalized customer service and advice further drives their importance in this market.
Online pharmacies have emerged as a rapidly growing segment in the distribution of intranasal corticosteroids. The convenience of ordering medications online and having them delivered directly to one's home has become increasingly popular, especially in the wake of the COVID-19 pandemic. Online pharmacies offer competitive pricing and often provide detailed information about the products, which appeals to tech-savvy consumers and those seeking to avoid the inconvenience of in-person shopping.
In summary, the global intranasal corticosteroids market is diverse and dynamic, with hospital pharmacies, drug stores, retail pharmacies, and online pharmacies each contributing to its growth. The accessibility and convenience provided by these various distribution channels ensure that patients can readily obtain the medications they need for managing nasal allergies and related conditions. As consumer preferences and healthcare delivery models evolve, these segments will continue to adapt and play vital roles in meeting the demand for intranasal corticosteroids.
Global Intranasal Corticosteroids Market, Segmentation by Geography
In this report, the Global Intranasal Corticosteroids Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Intranasal Corticosteroids Market Share (%), by Geographical Region, 2024
The global intranasal corticosteroids market is anticipated to witness significant growth over the forecast period from 2020 to 2030. Intranasal corticosteroids are commonly used to manage symptoms of allergic rhinitis and other nasal inflammatory conditions, offering relief by reducing inflammation and mucus production. This market's expansion is driven by the rising prevalence of allergic conditions, increasing awareness about the benefits of intranasal corticosteroids, and advancements in drug formulations.
In North America, the market is expected to maintain a dominant position due to high healthcare spending, widespread prevalence of allergies, and the presence of major pharmaceutical companies. The United States, in particular, leads this region with substantial market shares attributed to its advanced healthcare infrastructure and extensive research and development activities.
Europe follows closely, driven by the increasing incidence of allergic rhinitis and robust healthcare systems in countries like Germany, France, and the United Kingdom. The European market benefits from the presence of well-established pharmaceutical industries and a high adoption rate of advanced therapeutic options. Regulatory support and reimbursement policies further bolster the market in this region.
The Asia Pacific region is projected to witness the fastest growth during the forecast period. This surge is attributed to rising healthcare awareness, improving healthcare infrastructure, and increasing disposable incomes. Countries like China, India, and Japan are at the forefront, experiencing significant market penetration due to the growing prevalence of allergies and the expanding middle-class population seeking better healthcare solutions.
In the Middle East and Africa, the market growth is supported by improving healthcare access and the increasing burden of allergic diseases. While the market is relatively smaller compared to other regions, it is steadily expanding due to efforts to enhance healthcare infrastructure and services. Countries like Saudi Arabia, UAE, and South Africa are notable contributors to this growth.
Latin America presents a mixed scenario with varying growth rates across different countries. Brazil and Mexico are key markets within this region, driven by the increasing incidence of allergic conditions and improving healthcare systems. However, economic challenges and healthcare disparities in certain areas may slightly hinder the market's overall growth potential.
Overall, the global intranasal corticosteroids market is poised for robust growth, supported by increasing disease prevalence, advancements in healthcare, and rising awareness about effective treatment options. Each region presents unique opportunities and challenges, contributing to the market's dynamic and evolving landscape over the forecast period.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Intranasal Corticosteroids Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Pharmaceutical Innovations
- Advanced Formulations
- Environmental Allergens
-
Reimbursement Policies -Reimbursement policies play a significant role in shaping the global intranasal corticosteroids market, as they directly impact access to these medications for patients and healthcare providers. Here's an analysis of reimbursement policies across different regions:
In the United States, reimbursement for intranasal corticosteroids is typically covered by private health insurance plans, Medicare, and Medicaid. However, coverage and reimbursement rates may vary depending on the specific plan and formulary restrictions. Many insurance plans require patients to try generic alternatives before covering brand-name intranasal corticosteroids, which can affect market dynamics and brand preferences. Manufacturers often engage in pricing negotiations and rebate agreements with insurers to ensure favorable coverage and access for patients.
European countries vary in their reimbursement policies for pharmaceuticals, including intranasal corticosteroids. In countries with publicly funded healthcare systems, reimbursement decisions are often made by government agencies or health technology assessment (HTA) bodies based on cost-effectiveness assessments and clinical evidence. Reimbursement rates and patient co-payments can differ significantly between countries, influencing market access and pricing strategies for manufacturers. Private insurance coverage may also be available in some European countries, offering additional reimbursement options for patients.
Reimbursement policies for intranasal corticosteroids in the Asia-Pacific region vary widely among countries with different healthcare systems and regulatory frameworks. In countries with universal healthcare coverage, such as Japan and Australia, reimbursement decisions are typically made by government agencies or health insurance authorities based on clinical efficacy, safety, and cost-effectiveness. Private health insurance coverage may supplement public reimbursement in some countries, providing additional access for patients. However, affordability remains a key concern in many developing countries, where out-of-pocket expenses can limit access to essential medications.
Reimbursement policies for intranasal corticosteroids in Latin America and the Middle East & Africa vary depending on the healthcare system and regulatory environment of each country. In some countries, government-sponsored healthcare programs may provide reimbursement for essential medications, while in others, patients may rely primarily on out-of-pocket payments or private insurance coverage. Access to intranasal corticosteroids may be limited in regions with resource constraints and underdeveloped healthcare infrastructure, highlighting the need for improved affordability and access initiatives.
Overall, reimbursement policies significantly influence market dynamics and patient access to intranasal corticosteroids across different regions. Manufacturers must navigate diverse reimbursement landscapes and engage with payers to ensure optimal coverage and access for patients. Additionally, policymakers play a crucial role in establishing transparent and evidence-based reimbursement frameworks that promote affordability and equitable access to essential medications.
Restraints:
- High cost
- Limited awareness
- Alternative treatments
-
Generic competition -The global intranasal corticosteroids market has experienced significant competition from generic drugs, shaping the landscape of affordable treatment options for nasal inflammatory conditions. Generic competition arises when the patents for brand-name drugs expire, allowing other manufacturers to produce and market equivalent versions at lower costs. This competition has spurred accessibility and affordability, benefiting both patients and healthcare systems.
Generic versions of popular intranasal corticosteroids such as fluticasone propionate, mometasone, budesonide, and triamcinolone have become prevalent in the market. These generics offer comparable efficacy and safety profiles to their brand-name counterparts but at reduced prices, making them attractive options for healthcare providers and patients alike. The availability of generic alternatives has encouraged cost-conscious prescribing practices and facilitated broader access to essential medications.
Generic competition fosters innovation and drives down overall healthcare expenditure. Manufacturers of brand-name drugs may respond to generic competition by introducing novel formulations, delivery mechanisms, or combination therapies to differentiate their products and maintain market share. This dynamic environment encourages continuous improvement in drug development and enhances the quality of care for patients with nasal inflammatory conditions.
In summary, generic competition plays a crucial role in the global intranasal corticosteroids market by promoting affordability, accessibility, and innovation. It empowers patients with choices and encourages healthcare providers to prioritize cost-effective treatment options without compromising quality. As competition persists and generics continue to gain traction, the market is likely to witness further advancements and improvements in intranasal corticosteroid therapy.
Opportunities:
- Aging Population
- Increased Allergy Prevalence
- Improved Patient Compliance
-
Government Initiatives -Government initiatives play a crucial role in shaping the landscape of the Global Intranasal Corticosteroids Market, influencing aspects such as accessibility, affordability, and regulatory standards. Governments worldwide have implemented various strategies to address the growing burden of allergic rhinitis and other nasal conditions, thereby driving the demand for intranasal corticosteroids. Here are some key government initiatives impacting the market:
Governments enact policies and regulations to ensure the safety, efficacy, and quality of pharmaceutical products, including intranasal corticosteroids. Regulatory bodies such as the FDA in the United States, the EMA in Europe, and similar agencies worldwide set standards for product approval, manufacturing practices, and labeling requirements. Compliance with these regulations is essential for market entry and continued product sales.
Governments often launch public health campaigns to raise awareness about allergic rhinitis, its symptoms, and available treatment options. These campaigns aim to educate the public, encourage early diagnosis, and promote appropriate treatment, including the use of intranasal corticosteroids. By fostering greater awareness, governments help reduce the underdiagnosis and undertreatment of nasal conditions, thereby driving demand for relevant medications.
Some governments provide subsidies or reimbursement programs to make healthcare services and medications more affordable for citizens. By subsidizing the cost of intranasal corticosteroids or including them in reimbursement schemes, governments can improve patient access to these medications, especially for low-income populations. Such initiatives can significantly impact market demand and sales volumes.
Government funding for medical research plays a crucial role in advancing scientific knowledge and innovation in the field of intranasal corticosteroids. Research grants and funding support studies aimed at improving the efficacy, safety, and formulation of these medications, driving product development and market expansion. Government-funded research also helps address unmet medical needs and fosters collaboration between academia, industry, and healthcare providers.
Governments invest in healthcare infrastructure to enhance the delivery of medical services, including the diagnosis and treatment of allergic rhinitis and other nasal conditions. Infrastructure development may include the construction of healthcare facilities, the deployment of medical equipment, and the training of healthcare professionals. By improving healthcare infrastructure, governments support the diagnosis and management of nasal conditions, increasing the demand for intranasal corticosteroids.
Overall, government initiatives play a vital role in shaping the Global Intranasal Corticosteroids Market by influencing regulatory standards, raising awareness, improving affordability, funding research, and enhancing healthcare infrastructure. Collaboration between governments, regulatory agencies, healthcare providers, and pharmaceutical companies is essential for addressing the challenges posed by allergic rhinitis and ensuring access to effective treatments like intranasal corticosteroids on a global scale.
Competitive Landscape Analysis
Key players in Global Intranasal Corticosteroids Market include.
- GlaxoSmithKline plc.
- Merck Sharp Dohme
- Sunovion Pharmaceuticals Inc
- Sanofi
- Teva Branded Pharm
- McNeil Consumer Healthcare
- AstraZeneca
- Ivax Pharmaceuticals Incorporated
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Types
- Market Snapshot, By Indication
- Market Snapshot, By Dosage Form
- Market Snapshot, By End User Type
- Market Snapshot, By Region
- Global Intranasal Corticosteroids Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Pharmaceutical Innovations
-
Advanced Formulations
-
Environmental Allergens
-
Reimbursement Policies
-
- Restraints
-
High cost
-
Limited awareness
-
Alternative treatments
-
Generic competition
-
- Opportunities
-
Aging Population
-
Increased Allergy Prevalence
-
Improved Patient Compliance
-
Government Initiatives
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Intranasal Corticosteroids Market, By Drug Types, 2021-2031 (USD Million)
- Prescribed Drugs
- Beclomethasone
- Budesonide
- Ciclesonide
- Flunisolide
- Fluticasone Furoate
- Fluticasone Propionate
- Mometasone
- Triamcinolone
- OTC Drugs
- Budesonide
- Fluticasone Furoate
- Fluticasone Propionate
- Triamcinolone
- Global Intranasal Corticosteroids Market, By Indication, 2021-2031 (USD Million)
- Perennial Allergic Rhinitis (PAR)
- Seasonal Allergic Rhinitis (SAR)
- Nonallergic Rhinitis
- Global Intranasal Corticosteroids Market, By Dosage Form, 2021-2031 (USD Million)
- Intranasal Drops
- Intranasal Sprays
- Global Intranasal Corticosteroids Market, By End User Type, 2021-2031 (USD Million)
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- Online Pharmacies
- Global Intranasal Corticosteroids Market, By Geography, 2021-2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Intranasal Corticosteroids Market, By Drug Types, 2021-2031 (USD Million)
- Competitive Landscape
- Company Profiles
- GlaxoSmithKline plc.
- Merck Sharp Dohme
- Sunovion Pharmaceuticals Inc
- Sanofi
- Teva Branded Pharm
- McNeil Consumer Healthcare
- AstraZeneca
- Ivax Pharmaceuticals Incorporated
- Company Profiles
- Analyst Views
- Future Outlook of the Market